El cáncer de pulmón en mujeres by Enriqueta Felip

Get full text

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC) by Enriqueta Felip, Rafael Rosell

Get full text

The expanding importance of tissue sample analysis for biomarker testing in non-small cell lung cancer management and survival by Augusto Valdivia, Ilaria Priano, Nuria Pardo, Enriqueta Felip

Get full text

Symptoms and Experiences with Small Cell Lung Cancer: A Mixed Methods Study of Patients and Caregivers by D. Gwyn Bebb, Cressida Murray, Andromachi Giannopoulou, Enriqueta Felip

Get full text

Editorial: Multidisciplinary management of cancer patients with immune-related adverse events from checkpoint inhibitors by Mar Riveiro-Barciela, Mar Riveiro-Barciela, Mar Riveiro-Barciela, Enriqueta Felip, María E. Suarez-Almazor

Get full text

Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report by Oriol Mirallas, Marc Bosch-Schips, Nuria Pardo, Anton Aubanell, Maria Teresa Salcedo-Allende, Ana Callejo, Patricia Iranzo, Josep Tabernero, Enriqueta Felip

Get full text

Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy by Susana Cedres, Augusto Valdivia, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, Juan David Assaf-Pastrana, Enriqueta Felip, Pilar Garrido

Get full text

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer by Enriqueta Felip, Solange Peters, Alfredo Addeo, Martin Reck, Antonio Passaro, Christophe Von Garnier, Fiona Blackhall, David Planchard, Rafal Dziadziuszko, Filippo de Marinis, Hasna Bouchaab

Get full text

Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice by Mònica Sabaté Gallego, Mònica Sabaté Gallego, Eulàlia Pérez Esquirol, Núria Garcia Doladé, Xavier Vidal Guitart, Xavier Vidal Guitart, Maria-Josep Carreras Soler, Anna Farriols Danés, Enriqueta Felip, Enriqueta Felip, Irene Braña, Irene Braña, Joan Carles Galceran, Joan Carles Galceran, Rafael Morales Barrera, Rafael Morales Barrera, Eva Muñoz-Couselo, Eva Muñoz-Couselo, Antònia Agustí Escasany, Antònia Agustí Escasany

Get full text

Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients by Ana Callejo, Joan Frigola, Patricia Iranzo, Caterina Carbonell, Nely Diaz, David Marmolejo, Juan David Assaf, Susana Cedrés, Alex Martinez-Marti, Alejandro Navarro, Nuria Pardo, Ramon Amat, Enriqueta Felip

Get full text

Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study by Maria-Josep Carreras, Elena Tomás-Guillén, Anna Farriols, Berta Renedo-Miró, Carolina Valdivia, Jana Vidal, Cristina Saura, Joan Carles, Enriqueta Felip, Maria-Queralt Gorgas, Josep Tabernero, Josep Monterde

Get full text

790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head a... by Enriqueta Felip, Christian Mueller, Martin Forster, Tim Clay, Matthew Krebs, Leora Horn, Frederic Triebel, Enric Carcereny, Margarita Majem, Bernard Doger, Julio Peguero, Pawan Bajaj, Patricia Roxburgh, Chrystelle Brignone

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC by Enriqueta Felip, Ana Vivancos, Susana Cedres, Alex Martinez-Marti, Alejandro Navarro, Joan Frigola, Caterina Carbonell, Nuria Pardo, Ana Callejo, Mireia Soleda, Jose Jimenez, Javier Hernandez-Losa, Ramon Amat, Patricia Iranzo

Get full text

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial by Glenwood D. Goss, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Dolores Isla, Alessandro Morabito, Young J. Min, Andrea Ardizzoni, Shaun Bender, Agnieszka Cseh, Enriqueta Felip

Get full text

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer by Patricia Iranzo, Ana Callejo, Juan David Assaf, Gaspar Molina, Daniel Esteban Lopez, David Garcia-Illescas, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, Susana Cedres, Caterina Carbonell, Joan Frigola, Ramon Amat, Enriqueta Felip

Get full text

Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort by Susana Cedres, Juan-David Assaf, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, David Marmolejo, Alejandra Rezqallah, Caterina Carbonell, Joan Frigola, Ramon Amat, Anna Pedrola, Rodrigo Dienstmann, Enriqueta Felip

Get full text

A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology by Vladimir Lazar, Baolin Zhang, Shai Magidi, Christophe Le Tourneau, Eric Raymond, Michel Ducreux, Catherine Bresson, Jacques Raynaud, Fanny Wunder, Amir Onn, Enriqueta Felip, Josep Tabernero, Gerald Batist, Razelle Kurzrock, Eitan Rubin, Richard L. Schilsky

Get full text

Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. by Pablo Martinez, Javier Hernández-Losa, Ma Ángeles Montero, Susana Cedrés, Josep Castellví, Alex Martinez-Marti, Natalia Tallada, Nuria Murtra-Garrell, Alejandro Navarro-Mendivill, Victor Rodriguez-Freixinos, Mercedes Canela, Santiago Ramon y Cajal, Enriqueta Felip

Get full text

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small... by Enriqueta Felip, Juan-Miguel Cejalvo, Wolfgang Jacob, Tania Fleitas Kanonnikoff, Alejandro Navarro Mendivil, Maria Martinez Garcia, Alvaro Taus Garcia, Natasha Leighl, Ulrik Lassen, Morten Mau-Soerensen, Celine Adessi, Francesca Michielin, Ian James, Maurizio Ceppi, Max Hasmann, Martin Weisser

Get full text

595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab by Enriqueta Felip, Christian Mueller, Martin Forster, Tim Clay, Matthew Krebs, Frederic Triebel, Enric Carcereny, Ewa Kalinka, Margarita Majem, Bernard Doger, Julio Peguero, Chrystelle Brignone, Igor Bondarenko, Wade T Iams, Manuel Cobo Dols, Grygorii Ursol, Gema Garcia Ledo, Laia Vilà Martinez